Last updated: April 24, 2026
Who supplies SAPHRIS active pharmaceutical ingredient and key intermediates?
SAPHRIS (asenapine) is supplied through a multi-tier small-molecule supply chain: API manufacturers produce asenapine bulk drug substance, which is converted into finished-dose product (tablet). Final product supply is handled by branded and/or authorized generic manufacturers with quality systems aligned to FDA requirements.
No reliable, single-source public procurement roster exists that names all SAPHRIS API and packaging suppliers by company for every market. Public records typically identify: (i) NDA/ANDA holders and label controls, (ii) listed manufacturers in regulatory submissions, and (iii) facility-level manufacturing assignments on FDA product pages and regulatory datasets.
Which parties are publicly documented as SAPHRIS finished-dose manufacturers?
Publicly visible manufacturer information for SAPHRIS is usually captured through FDA product labeling/manufacturer fields and FDA inspection records. The most actionable supplier view for investors and R&D procurement is the facility-level manufacturing and repackager/importer data reflected in the FDA label and product listing systems.
What supplier layers exist for SAPHRIS?
For procurement and diligence, SAPHRIS supply chain typically breaks into these layers:
-
API (asenapine) bulk drug substance
- Synthesized small molecule API
- Controlled intermediate and final crystallization steps
- Sterility is not applicable; non-sterile solid oral dose
-
Drug product manufacturing
- Direct compression or formulation into oral solid dosage form
- In-process controls for assay, impurities, and blend uniformity
- Finished product testing and stability
-
Packaging and labeling
- Blister packs or unit-dose formats (market-dependent)
- Cartoning, labeling, and serialization (where applicable)
How to read “supplier” for SAPHRIS in diligence terms
For business decisions, “supplier” usually means one of three distinct entities:
- NDA/label holder (market authorization holder)
- Drug product manufacturer(s) (site(s) that make finished dosage)
- API manufacturer(s) (site(s) that produce asenapine bulk drug substance)
Each impacts supply continuity risk differently: API shortages propagate into finished dose quickly; packaging bottlenecks can delay launches even with available API.
SAPHRIS: practical supplier mapping (facility-level)
SAPHRIS is an FDA-approved asenapine product. The supplier mapping that is most consistently auditable is facility-level manufacturing assignment and label-associated manufacturer listings. Those listings are discoverable from FDA drug product labeling and FDA product databases, then cross-checked against inspection outcomes for continuity risk.
Actionable supplier dossiers should be built from:
- FDA product label manufacturer sections (drug product and sometimes packaging)
- FDA inspection dataset (Form 483 outcomes by facility)
- Market authorization and distributor fields (importer/repackager, where present)
What supply risk signals matter for SAPHRIS?
Small-molecule API supply is sensitive to:
- single-site crystallization/cycling capacity constraints
- impurity profiles and regulatory acceptance for changes
- API batch timing affecting finished dose release
For diligence:
- track facility inspection outcomes and warning letters (if any)
- monitor FDA shortage signals at the NDC level
- map alternate sites for drug product and packaging
Where to locate SAPHRIS supplier facts in public regulatory sources
The supplier list you can rely on for SAPHRIS is derived from these public sources:
- FDA Drug Product Labeling (Structured Product Labeling): identifies manufacturer fields used for label control and contact
- FDA National Drug Code (NDC) product listings: ties a given dosage form/strength to listed establishments
- FDA Inspection records (facility-level): adds continuity risk context
- FDA Drug Shortages database (if shortages are active): validates real supply constraints
Key Takeaways
- SAPHRIS “suppliers” are best defined as (1) label authorization holder, (2) drug product manufacturer(s), and (3) API manufacturer(s), not a single monolithic vendor list.
- Publicly auditable supplier identification for SAPHRIS should be anchored to FDA labeling and product listing/manufacturer fields, then validated via facility inspection records.
- For procurement and R&D continuity, build a facility-level supplier map across drug substance, drug product, and packaging with inspection and shortage signals at the NDC level.
FAQs
1) Is there a single public list of all SAPHRIS API suppliers?
No. Public data is typically fragmented across FDA label manufacturer fields, establishment listings, and facility inspection records.
2) What is the most defensible “supplier” definition for SAPHRIS procurement?
Use the FDA label/product listing manufacturer fields for drug product and the establishment-level listings for API where disclosed through regulatory records.
3) What creates the biggest SAPHRIS supply risk: API or packaging?
API constraints usually drive shortages faster for oral solids, while packaging bottlenecks can delay release even with API in-hand.
4) How do investors validate SAPHRIS manufacturing continuity?
They validate facility-level manufacturing sites via FDA inspection records and monitor NDC-level shortages.
5) Do supplier changes require regulatory work for asenapine?
Yes. Changes in API source, synthesis route, or drug product sites typically require comparability and regulatory acceptance under the NDA change framework.
References
[1] U.S. Food and Drug Administration. Drug Products and Label Information (Structured Product Labeling). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] U.S. Food and Drug Administration. NDC Directory / Drug Listing information. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
[3] U.S. Food and Drug Administration. FDA Inspections, Compliance, Enforcement, and Criminal Investigations. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations
[4] U.S. Food and Drug Administration. Drug Shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
